Cell line · CVCL_A442
TMD8
Cancer cell line, Homo sapiens. Diffuse large B-cell lymphoma activated B-cell type. 33 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Cite this record
ConductScience Library. TMD8. Cell lines, record CVCL_A442. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_A442
On this page
Cell line
As Cellosaurus gives it.
- Name
- TMD8
- Accession
- CVCL_A442
- RRID
- RRID:CVCL_A442
- Synonyms
- TMD-8, Tokyo Medical and Dental university 8
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 62Y
- Category
- Cancer cell line
- Diseases
- Diffuse large B-cell lymphoma activated B-cell type (NCIt C36081); Diffuse large B-cell lymphoma (ORDO Orphanet_544)
- Derived from
- Bone marrow (in situ)
- Entry created
- 2012-06-06
- Entry updated
- 2026-03-31
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers33
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models. | Blood Neoplasia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A 3D genome atlas of human tonsil and the role of loop extrusion in B cell somatic hypermutation. | Science | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma. | Blood Neoplasia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The tropomyosin 3.1/3.2 inhibitor ATM-3507 alters B-cell actin dynamics and impairs the growth and motility of diffuse large B-cell lymphoma cell lines. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. | Blood Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| EZB-type diffuse large B-cell lymphoma cell lines have superior migration capabilities compared to MCD-type. | Br J Haematol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. | Cell Commun Signal | 2024 | Its Methods give the RRID and name the line | PubMed | |
| IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 33
See all 33 papersRelatives14
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | HyCyte TMD8 hBTK_p.L528W_c.1583T>G cell line | CVCL_F4KA | Cell lines | |
| Derived from it | TMD8-BTK-A428D-KI-1B4 | CVCL_E8IZ | Cell lines | |
| Derived from it | TMD8-BTK-C481F-KI | CVCL_E8J0 | Cell lines | |
| Derived from it | TMD8-BTK-C481S-KI-1B3 | CVCL_E8J1 | Cell lines | |
| Derived from it | TMD8-BTK-C481S-KI-1C6 | CVCL_E8J2 | Cell lines | |
| Derived from it | TMD8-BTK-C481Y-KI-1A2 | CVCL_E8J3 | Cell lines | |
| Derived from it | TMD8-BTK-C481Y-KI-1B2 | CVCL_E8J4 | Cell lines | |
| Derived from it | TMD8-BTK-HiBiT-KI-1B1 | CVCL_E8J5 | Cell lines | |
| Derived from it | TMD8-BTK-L528W-KI | CVCL_E8J6 | Cell lines | |
| Derived from it | TMD8-BTK-T474I-KI-1A1 | CVCL_E8J7 | Cell lines |
1 to 10 of 14
See all 14 relativesCell banks1
| Cell bank | Catalog number | Status |
|---|---|---|
| CLS | 305729 |
Source CLS
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_A442
GET https://conductscience.org/api/cell-lines/v1/CVCL_A442/papers?page=2